Nintedanib for Unicentric Castleman Disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a medication called nintedanib for people with a rare condition called Unicentric Castleman disease (one area of lymph nodes affected) that cannot be fully removed by surgery. The goal is to see if nintedanib can help shrink the tumor or control symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with hyaline-vascular Unicentric Castleman disease (a specific type that affects only one area of lymph nodes).
- Your Castleman disease tumor cannot be fully removed by surgery, or you have chosen not to have surgery.
- You are covered by the French national health insurance system.
- You are not at high risk for bleeding (e.g., no bleeding disorders, not taking blood thinners).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a worldwide registry that collects basic medical information from people diagnosed with Castleman disease. It helps researchers learn about real-world care and outcomes across different ages and care settings.
This trial is looking back at the medical records of people with a rare condition called Castleman's disease to see how well the drug Siltuximab worked for them in everyday hospital care, not in a research setting. The goal is to learn more about how safe and effective the drug can be for patients in real life.
This trial tests the drug ruxolitinib for people with idiopathic multicentric Castleman disease (iMCD) whose symptoms are not well controlled by standard anti-IL-6 therapy. Ruxolitinib is a pill taken by mouth that may help reduce inflammation and improve symptoms.
This study tests a drug called pacritinib for people with KSHV-associated multicentric Castleman disease (MCD) or KSHV-associated inflammatory cytokine syndrome (KICS). It aims to see if the drug can help control symptoms and inflammation caused by these conditions.
This study looks at how KSHV-associated multicentric Castleman disease naturally progresses over time, without necessarily testing a new treatment. It may help doctors better understand the disease and what changes to watch for, which could guide future care.
This study tests new methods to diagnose lymphoma and multicentric castleman disease, which are conditions that can affect people with HIV. It may help find these diseases earlier and more accurately.
Hear when a new Castleman Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.